Clinical Trials · NCT07505745
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Hudson Biotech
- Enrollment
- 120
- Start date
- Feb 2026
- Locations
- 1 site, China
- Primary endpoint
- Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index)